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Fulminant or subacute hepatic failure (FHF/SAF) are characterized by 
massive necrosis of hepatocytes caused by any of a wide variety of hepatic 
insults (viral infection, chemicals, metabolic disorders, etc.). The condition 
is defined as true fulminant failure when it occurs within 8 weeks of the 
onset of the symptoms and subacute when the liver failure becomes evident 
sometime between the eighth and the twentieth week after the onset of 
the symptoms of liver disease. True FHF presents with progressive 
deterioration of hepatic function, leading to deepening jaundice, rapid onset 
and progression of hepatic encephalopathy, "foetor hepaticus," edema, 
ascites, severe coagulation disturbances and, in the later stages, hypogly-
cemia. hepatorenal syndrome, sepsis, acidosis, multiorgan failure. and 
eventually death. FHF is a disease syndrome with an extremely high 
degree of morbidity and mortality. The mortality is age- and etiology-
dependent and averages 80 per cent when Stage IV coma has been reached, 
despite intensive medical treatment. 1-1 In adults who reach stage IV coma, 
the mortality is 95 per cent or greater. SAF presents \\;th a slower 
progression, but with a similar outcome in most of the cases. While liver 
transplantation (ortho- or heterotopic) has always been a tempting alterna-
tive to intensive medical therapy for this condition, it is only recently that 
whole organ liver replacement has achieved a success rate that justifies its 
use for FHF/SAF. J..,} 
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In this article, the pre-. intra-, and postoperative management and 
decision-making process relative to liver transplantation for fulminant and 
subacute hepatic failure will be discussed, followed by a presentation of the 
results achieved by our group with orthotopic liver transplantation for these 
indications. 
ETIOLOGY 
A wide variety of causes for FHF have been identified: viruses (hepatitis 
A, B and non-A, non-B), toxic substances (acetominophen), volatile solvents 
and anesthetics (halothane). and a few metabolic disorders (especially 
fulminant Wilson's disease). While a certain percentage of the patients with 
FHF secondary to chemical hepatitis (acetaminophen) may recover with 
intensive medical treatment. fulminant Wilson's disease, halothane hepati-
tis, and most cases of fulminant viral hepatitis are uniformly fatal or nearly 
so (>95 per cent) \\;thout liver transplantation. 6 7 Therefore, the etiology 
of the liver failure is a crucial consideration in deciding whether and when 
liver transplantation ought to be applied for an individual with fulminant 
or subacute hepatic failure. 
Preoperative ~fanagement 
Fulminant liver necrosis is usually the result of a viral infection (type 
A, B. or non-A, non-B) or chemical dama~eI either from drugs (involving 
hypersensitivity or overdosage) or from toxic substances. Establishing an 
etiology is important not only from an academical point of \'iew, but also 
to guide the therapy. avoid further parench\'mal damage, and establish a 
prognosis. A careful history \\'ill usually reveal recent exposure to drugs or 
other chemicals. or risk factors for viral hepatitis. A family history of liver 
failure may provide a hint to the possibility of fulminant Wilson's disease 
as the etiology for liver failure. 
:\. complete serological profile for viral liver disease (A, B, non-A, non-
B, EB\', HSV, C~fyDy is obligatoJ"\', as well as a toxin screen, and measure-
ment of urinary copper and seru~ ceruloplasmin levels. Intense hemolysis 
is strongly suggestive offulminant \\'ilson's diseaseh. 7 or hepatitis associated 
\\-ith gluco-6-phosphate defiCiency, whilt' p;ranulocytopenia with or without 
lymphocytosis suggests fulminant non-A, non-B hepatitis or one of the 
other more esoteric causes of viral hepatitis. 
A preliminary determination of the probable prognosis is essential in 
deciding whether transplantation is indicated and what the timing should 
be. The presence of rapidly progressing encephalopathy, severe hemolysis, 
development of cerebral edema, and/or a rapidly shrinking liver are all 
ominous signs and should alert the attending physicians that irreversible 
liver damage is likely and that liver transplantation is necessary and 
imminent. Transplantation in the presence of Stap;e IV coma, bacteremia. 
severe hepatorenal syndrome. spontaneous bacterial peritonitis or other 
types of sepsis, and/or massive gastrointestinal hemorrhage has a very poor 
prognosis. The decision to transplant a patient "ith fulminant hepatic failure 
is one of the most difficult and agonizing that a physician will ever face. 
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Figure J. The indication for OLTx increases until the early sta)!;e 1\' coma. then decreases 
rapidly, 
The favorable "window" for transplantation may be extremely brief. and 
temporizing may adversely affect the patient's chance for sur\'ival (Fig. 1). 
Generally. rapid deepening of the hepatic coma. a steady prolongation of 
the prothrombin time (unresponsive to infusion of fresh frozen plasma), the 
development of the hepatorenal svndrome. hypoglycemia. and uncorrecta-
ble metabolic acidosis are signs of impending death that require urgent 
transplantation. Frequent asessment of the patient's condition. as often as 
hourly, is necessary in order to be able to make a proper decision. As a 
result of the considerable improvement in liver transplantation results 
experienced during the past 5 or 6 years, the decision to proceed with liver 
tr.msplantation in cases of FHF or SAF (also called "Iate-onset hepatic 
failure") is less difficult than preViously, 
It is essential to place the patients with FH F on the urgent transplant 
list as soon as they are admitted to hospital. Age, blood type, height. and 
weight must be obtained to permit a good donor-recipient match. if 
possible; matching for the blood type is desirable, though not essential. 
while a good size match is highly indicated for technical reasons, The 
clinical situation of the patient must be assessed every time a potential 
donor organ becomes available, and a liver transplant should be performed 
if the patient's condition is thought to be irreversible .... ithout organ 
replaeement and if the donor is suitahle. If the situation is particularly 
desperate, a liver that is of a different blood type and/or size can be used. 
even if such grafts result in less than ideal transplant outcomes. A brief, 
but intensive work-up should be performed, including a determination of 
the hlood group, sonography to assess the patency of the portal and 
suprahepatic veins, viral hepatitis and toxic screens. urine copper excretion, 
and serum ceruloplasmin leve\. All potential infection should be avoided 
and any existing infection must be treated early and aggressively. The 
coagulation status should be corrected as much as possible with fresh frozen 
plasma (FFP) infusions and the administration of exogenous vitamin K. 
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while the renal function must be guaranteed. The nutritional status must 
be maintained by way of an enteral or parenteral route, using hepatopro-
tective formulas. If the patient is obtunded, nasogastric suction is recom-
mended to prevent aspiration pneumonia, and the stomach pH should be 
alkaline as a result of the administration of antacids. If anv doubt exists as 
to the possibility of aspiration, the patient's airway must b~ protected with 
prophylactic intubation. Any increase in the intracranial pressure should 
be prevented and controlled at the earliest signs of onset by infusions of 
mannitol if the renal function is adequate or with ultrafiltration if the kidney 
function is impaired. Plasmapheresis or charcoal hemofiltration may be 
used as temporary measures, particularly in the case of drug toxicity or 
fulminant Wilson's disease. 
A point that has not been emphasized sufficiently in the literature is 
that any patient with fulminant or subacute hepatic failure should be 
transferred to a center that performs liver transplants as early as possible. 
Even if recovery is a possibility, these patients can be managed and more 
easily transplanted in the appropriate setting; unfortunately, all too often 
these patients are referred to a transplant center either when they are so 
far advanced that transportation is no longer possible, or they experience 
brain stem herniation, hypoglycemia. or central nervous system bleeding 
during the transfer period. 
Intraoperative ~fanagement 
The intraoperative management of patients with fulminant or subacute 
hepatic failure undergoing transplantation is extremely complex and rep-
resents a real challenge to the anesthesia team. Although rather straight-
forward technically, a transplant under these conditions is a challenge for 
the surgeon because the operation must be performed in a virtually perfect 
fashion in order to avoid large blood volume losses and/or blood pressure 
drops. which could have the potential of causing irreversible damage to a 
brain already in jeopardy. Fortunately transplantation for fulminant hepatic 
failure occurs in a patient without previous liver disease and. hence. 
without portal hypertension. On the other hand. in such cases cross-
clamping of the portal vein and inferior vena cava. with the obligatory 
reduction of the venous return to the heart to less than half of the normal 
levels. can be disastrous. particularly in a patient already haVing brain 
edema and advanced hepatic encephalopathy. This factor largely explains 
the dismal results of liver transplantation for fulminant or subacute hepatic 
failure during the "pioneer" years. With the introduction of the venovenous 
by-pass without systemic heparinization to the transplantologist's armamen-
tarium, most if not all of the vascular imbalances associated with liver 
transplantation have been eliminated. 
The main challenge of liver transplantation for acute or subacute 
hepatic failure rests with the anestheSiologist. who must deal with and 
correct the problems related to a state similar to septic shock (increased 
cardiac output and decreased peripheral vascular resistance). compounded 
by severe coagulopathy, acid-base imbalances. renal dysfunction with a 
decreased or absent urine output, as well as a multitude of electrolyte 
imbaJances. particularly at the end of the anhepatic phase of the procedure. 
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The anest~esia team is, therefore, faced with an extremely complex situation 
that reqUires constant attention throughout the procedure. The correction 
of fluid and electolyte imbalances is done in a continuous manner; the 
coagulati~~ is ~odulated and enhanced by the use of FFP, platelet and 
cry~pre~lpltate mfusion, as well as by administration of epsilon-aminoca-
prOic aCid when fibrinolysis occurs. Frequent thromboelastogram (TEG) 
mon~to~ng .is required to accomplish these goals. Intraoperative EEG 
momtonng IS recommended, since the presence of seiZure activity cannot 
be ascertained othef\\;se under general anesthesia. The use of vas~pressors 
for the control of hypotension during the operative procedure has to be 
extremely cautious, since they can damage the allograft bv decreasing the 
splanchnic blood flow. . 
Postoperative ~fanagement 
The postoperati\'e management of individuals transplanted for FHF or 
SAF is different from that utilized in other patients who have been 
transplanted, because these FHF/SAF patients may still have residual renal 
failure. requiring adjustment of their cyclosporine (CsA) doses and as a 
result. may need the addition of other immunosuppressive agents to 
compensate for the lower CsA level (azathioprine, anti thymocyte globulin 
[ATG], or monoclonal antibody preparation [OKT3jl and/or hemodialvsis 
until the renal function resumes. In such cases. the liver function mu;t b; 
monitored more carefully than usual. as primary nonfunction of the allograft 
tends to be more lethal in patients whose brain is already impaired as a 
result of preexisting encephalopathy; if the allograft function dUring the 
early postoperative period is not excellent, retransplantation may be per-
formed as an emergency to limit further patient deterioration. 
RESULTS OF LIVER qoA~pmiA~qAqflk FOR cri~ff~A~q A~a 
SUBACUTE HEPATIC FAILURE 
Our experience includes 40 patients who underwent liver transplan-
tation for fulminant and subacute hepatic failure in a series of 1.170 patients 
transplanted between ~EarchI 1963 and July 20. 1987. Of these 40 patients, 
17 (42.5 per cent) were male and 23 (57.5 per cent were female. Their 
ages ranged from 4 to 62 years (overall mean 21. 75), \\;th a range of 4 to 
62 years (mean :21.41) for males and a range of 6 to 57 years (mean 22.(0) 
for females. Eight patients (20 per cent) had hepatitis type B (3 male and 
5 female). fifteen (37.5 per cent) had hepatitis type non-A. non-B (6 male, 
9 female), six \ 15 per cent) had fulminant chemical toxicity (4 male, 2 
female), ten (25 per cent) had fulminant Wilson's disease (4 male, 6 female) 
and one female had FHF of unknown etiology (possibly Reye's syndrome) 
(Fig. 2). Thirty (75 per cent) presented with acute hepatic failure (14 male 
and 16 female) and ten (25 per cent) had subacute hepatic failure (3 male 
and i female). Six (15 per cent) had very mild or no encephalopathy (2 
male, 4 female), eight (20 per cent) had stage I hepatic coma (4 male and 
4 female), five (12.5 per cent) had stage II hepatic coma (2 male and 3 
female), seven (17.5 per cent) had stage III hepatic coma (2 male. 5 female) 
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Figure 2. Fulminant and subacute hepatic failure diagnoses. 
and fourteen (35 per cent) had stage IIIIIY or 1\' coma (6 male. 8 female). 
The record was incomplete in one case and the degree of coma could not 
be determined retrospectively (Fig. 3). The interval from the onset of 
clinical disease to the time of transplantation ranged from 0 to 25 weeks 
(mean 5.37). the total pretransplant hospital time ranged from less than 1 
to 40 days (mean 10.6). the pretransplant ICt" time ranged from 0 to 6 
days (mean 2.0), while the time spent on a respirator before transplantation 
ranged from 0 to 5 days (mean 0.95). 23 patients (57,5 per cent) survived 
(10 male and 13 female), while 17 (42,5 per cent) died (7 male and 10 
female) (Fig. 4). There was no Significant statistical difference in the total 
pretransplant, hospital and ICC time between the survivor and nonsurvivor 
groups, A trend toward a longer time spent on the respirator prior to 
transplantation was evident in nonsurvivors (0,76 dan for survivors versus 
1.18 days for nonsur\,ivors), although the number of patients in this group 
was too small to achieve a statistical significance, Although in previous 
studies~ a Significant negative impact of retransplantation on survival was 
reported. we did not observe such a relationship in this series. In fact. in 
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Figure 3. Fulminant and subacute hepatic failure: Degree of coma. num~r of patients. 
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Figure 4. Fulminant and subacute hepatic failure: Survival by sex. 
this series, the only patient who received four consecutive liver transplants 
survived, On the other hand, it appears that the need for verv earlv 
retransplantation may adversely affect survival. . . 
Of the -10 patients in our series, 22 (55 per cent) had a good neurological 
outcome, meaning a complete recovery of their neuropsychic performance, 
\\,"ithout any evidence of neurological sequellae; 2 patients (5 per cent) had 
a fair neurological outcome with persistence of some sequellae; finally, 16 
patients (40 per cent) had a poor neurological outcome (Fig. 5). This latter 
group included all the non survivors who never awoke after the transplant 
operation, as well as 2 patients who sun'ived for at least 6 months or longer 
but never regained sufficient neuropsychic capacity to function independ-
ently. There was no statistical difference in the total pretransplant, hospital, 
and lCU time between the patients with a good and a poor neurological 
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Figure 5, Fulminant hepatic failure: Neurological outcome. 
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when the time spent in the ICU and on a respirator preoperatively was 
considered (1. 77 days for a good neuropsychiatric outcome versus 2.25 for 
a poor outcome and 0.65 days vs. 1.37 days respectively). The number of 
patients in each group, however, was too low to achieve a statistical 
difference. There was a notable difference between good and poor neuro-
logical outcomes when the degree of coma was analyzed: 9 out of 16 patients 
with a poor outcome (56.25 per cent) had stage IIIIIV or IV coma, while 
only 4 out of 22 (18 per cent) patients with a good neurological outcome 
had advanced coma grade. When the patients who required retransplanta-
hon were analyzed, the most lethal of the causes for retransplantation was 
found to be the primary nonfunction of the allograft; because only one out 
of five (20 per cent) survived, this is consistent with our previous findings. s 
DISCUSSIOX 
Considering the dismal prognosis of fulminant and subacute hepatic 
failure. it would seem to be a prime indication for liver replacement. l'ntil 
just a few years ago, this was not feasible in practice, as the results "ith 
liver transplantation. in general, were rather poor, and to this the additional 
handicaps associated with FHF would have to be added. Since the intro-
duction of CsA, the results with liver transplantation have impTO\ed 
enormously and with the greater availability of donors, liver replacement 
for FH F has become a reasonable proposition. All other methods of 
temporary hepatic support utilized have only prOVided additional time 
during which a donor organ can be actively sought, but none of these 
represent a valid definitive alternative to liver transplantation. These 
methods should be used routinely whenever possible during the pretrans-
plant period to slow down the speed of the hepatic failure and to allow the 
patient to be transplanted while still being in the best possible condition. 
Notable in this respect are the use of activated charcoal hemofiltration. 
plasmapheresis, and the use of prostacyclin infusion to prevent platelet 
aggregation. I. l 
It is of some interest that oniv one of the cases of FHF caused bv 
hepatitis B virus infection, who rec~ived 100 ml of hyperimmune globuli~ 
during the operation, has converted to antigen negative/antibody positive; 
one other patient, the first perioperati\'e survivor of a transplant for FHF 
performed in 19i4, appeared to be hepatitis B negative by RIA after the 
transplant procedure, but the subsequent records for this patient are 
incomplete and he died 3 months later of complications of the transplant 
unrelated to his original disease. One patient died on the operatin!!: table. 
All the others (62.5 per cent) have continued to be serologically positive 
after the transplant, and all but one of these had recurrence of the disease 
(proven by biopsy). They are all stable and well now, although with active 
low-grade disease, 8 months to 3 years after their transplant. There is no 
doubt that most of the patients with FHF regardless of etiology have a 
survival of only 20 per cent or less with even the most intensive medical 
treatment, while transplantation offers immediate survival of at least 55 per 
cent. 
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There is little doubt, from our data as well as that of others, that liver 
transplantation for FHF/SAF is not only justified, but indicated and that. 
\\;th continuous improvement of the technique, transplantation should be 
offered as an alternative earlier than ever before and in some cases even 
before spontaneous recovery cat! be ruled out completely, 
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